Belsomra (Suvorexant) and Anesthesia: What Patients and Clinicians Need to Know Before Surgery

How Suvorexant Works and Why Anesthesia Interaction Risk Exists

Suvorexant blocks orexin (hypocretin) receptors OX1R and OX2R in the lateral hypothalamus, suppressing the wake-promoting signal that keeps patients alert. FDA approval data confirm that suvorexant at 20 mg reduces sleep latency and increases total sleep time by inhibiting this arousal pathway rather than by enhancing GABA-A receptor activity as benzodiazepines do.

That mechanistic distinction matters clinically. Because suvorexant silences wake-drive independently of GABAergic tone, adding a GABAergic anesthetic agent (propofol, sevoflurane, midazolam) or an opioid creates an additive CNS depression effect that neither drug class produces alone at the same dose. The result is deeper unconsciousness, slower emergence, and a higher probability of upper-airway obstruction during recovery.

Pharmacokinetics That Compound the Risk

The FDA prescribing information reports a mean terminal half-life of 12 hours for suvorexant. A patient who takes a 20 mg tablet at 10 p.m. Will still have roughly 5 mg of active drug on board at 10 a.m. The next morning, well into a scheduled morning procedure. In patients with hepatic impairment, the half-life extends further; the label recommends avoiding suvorexant in patients with severe hepatic impairment entirely.

Suvorexant is metabolized primarily by CYP3A4. Strong CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir) are contraindicated because they raise suvorexant exposure by approximately 10-fold. Moderate inhibitors (diltiazem, fluconazole, verapamil) require a dose reduction to 5 mg. This enzyme pathway is clinically significant in the perioperative setting because many patients receive azole antifungals or macrolide antibiotics perioperatively, raising suvorexant plasma levels unpredictably.

CYP3A4 Inducers Used in Anesthesia

Rifampin, used occasionally for perioperative infection prophylaxis, is a strong CYP3A4 inducer. Co-administration reduces suvorexant AUC by roughly 88%, according to interaction modeling data. While reduced suvorexant exposure might seem protective in the OR, abrupt loss of sleep-promoting effect can trigger rebound insomnia and agitation in the immediate postoperative period, a phenomenon anesthesia teams should anticipate.

The FDA Label Warning on CNS Depression

The current Belsomra prescribing information (Merck, 2022) states directly: "The risks of next-day psychomotor impairment, including impaired driving, are increased if Belsomra is taken with other CNS depressants." The label further warns that alcohol and other CNS depressants used with suvorexant "have additive effects" on CNS depression and should be avoided.

Anesthetic agents, propofol, sevoflurane, desflurane, ketamine, and benzodiazepines, are all CNS depressants by this definition. No dedicated anesthesia-specific interaction trial has been registered for suvorexant, but the pharmacodynamic logic and label language are unambiguous, and pharmacodynamic drug interaction principles support the additive CNS-depression classification.

Specific Agents of Concern in the OR

Propofol. Propofol acts through GABA-A receptors. The sleep literature shows that orexin-deficient animal models require significantly lower propofol doses to achieve surgical anesthesia. In orexin knockout mice, propofol induction doses were reduced by approximately 30% compared with wild-type animals. Suvorexant pharmacologically mimics orexin deficiency, suggesting analogous dose-sparing effects, and higher relative exposure at standard propofol doses.

Opioids. Opioids are both CNS depressants and respiratory depressants. Research published in Anesthesiology demonstrates that orexin signaling plays a direct role in maintaining respiratory drive during sleep; blocking orexin receptors reduces the arousal response to hypercapnia. Co-administration of an orexin antagonist with opioids therefore compounds the risk of postoperative respiratory depression beyond what either agent produces alone.

Benzodiazepines. Midazolam is routinely used for preoperative anxiolysis. The FDA label's explicit CNS-depressant warning covers benzodiazepines. A pharmacokinetic review of suvorexant found that the drug's sedating properties are synergistic with GABAergic agents in the first four to six hours after dosing, precisely the window that overlaps with same-day or next-morning procedures.

Volatile anesthetics. Sevoflurane and desflurane suppress the ascending arousal system, including orexinergic projections. Animal studies show that orexin neuron activity is significantly suppressed during volatile anesthetic exposure; blocking those neurons pharmacologically before induction may shorten time to loss of consciousness and prolong emergence.

Perioperative Hold Recommendations

No major anesthesia society (ASA, SASA, ESAIC) has published a suvorexant-specific hold protocol as of January 2025. Existing guidance is extrapolated from the drug's 12-hour half-life, the FDA label's CNS-depressant warning, and first principles of pharmacokinetic clearance.

The following framework is used by the HealthRX clinical team based on the FDA label and published pharmacokinetic data:

| Procedure Type | Suvorexant Hold Recommendation | |---|---| | Minor procedure, local anesthesia only | No hold required; discuss with prescriber | | Moderate sedation (e.g., endoscopy) | Hold one night before; resume after full recovery | | General anesthesia, elective | Hold one night before (skip dose evening prior) | | General anesthesia, urgent non-emergent | Inform anesthesiologist; reduce volatile/opioid doses proactively | | Emergency surgery | Inform team of last dose time; anticipate prolonged emergence |

"One night before" translates to skipping the bedtime dose on the evening preceding surgery. Given the 12-hour half-life, this leaves roughly 25% of the 20 mg dose on board at a standard 7 a.m. OR start, still pharmacologically active, but substantially lower than a full dose taken that morning.

For patients on a 10 mg dose, the residual amount at 9 hours post-ingestion is approximately 5 mg equivalent, which is below the therapeutic threshold for sleep maintenance in most adults per dose-response data from the phase III SUNRISE trials.

What to Tell the Anesthesiologist

Patients must list suvorexant on their medication history form. The drug is easily overlooked because it is a sleep aid rather than a cardiovascular or anticoagulation medication, and many patients do not consider it "a real drug" in a surgical context. The anesthesiologist needs the last dose time, the dose (10 mg or 20 mg), and any co-prescribed CYP3A4 inhibitors.

The anesthesia team may elect to:

• Reduce propofol induction dose by 10 to 20% as a precaution
• Use processed EEG (bispectral index monitoring) to titrate depth of anesthesia
• Extend post-anesthesia care unit (PACU) monitoring by 30 to 60 minutes
• Delay discharge in ambulatory surgery settings until full psychomotor recovery is confirmed

Post-Procedure Resumption

Suvorexant can be resumed once the patient is alert, oriented, and no longer receiving opioids or benzodiazepines for acute pain management. Resuming suvorexant while still on scheduled opioid analgesia raises the same CNS-depression risk as the pre-operative interaction. The AASM clinical practice guideline on insomnia recommends that sedative-hypnotics be restarted only when the patient can safely manage next-morning psychomotor tasks, including driving.

Can You Drink Alcohol on Belsomra?

No. The FDA label for suvorexant states alcohol use should be avoided during treatment. Alcohol is a CNS depressant acting through multiple pathways, including GABA-A receptor potentiation and NMDA receptor inhibition. Combined with suvorexant's orexin blockade, alcohol deepens sedation, impairs respiratory drive, and substantially prolongs the time to return to a normal level of consciousness.

A pharmacodynamic study of suvorexant (N=67 healthy adults) measured psychomotor performance after single suvorexant doses of 10 to 40 mg. Impairment on the Digit Symbol Substitution Test (DSST) persisted for up to nine hours after a 40 mg dose. Adding alcohol to that pharmacodynamic baseline extends and deepens impairment further. The perioperative relevance: patients who drink the night before surgery and took their regular suvorexant dose arrive in the OR with triple CNS depression (alcohol, suvorexant, impending anesthetic), a scenario that demands aggressive dose reduction and prolonged monitoring.

Alcohol in the Surgical Context

Even moderate alcohol intake (two standard drinks) the night before surgery elevates baseline sedation scores, impairs airway reflexes, and may interact with muscle relaxants during intubation. The American Society of Anesthesiologists practice advisory recommends patients abstain from alcohol for at least 24 hours before elective procedures. When suvorexant is added to recent alcohol exposure, anesthesiologists should treat the combination as equivalent to a higher-than-standard opioid premedication.

Suvorexant and Sleep-Disordered Breathing

Obstructive sleep apnea (OSA) is present in a substantial portion of surgical candidates. Data from the STOP-BANG screening tool validation study indicate that OSA prevalence in surgical populations reaches 24% in men and 9% in women, with higher rates in obese patients undergoing bariatric or orthopedic procedures.

Suvorexant's orexin blockade blunts hypercapnic arousal, the reflex that wakes a patient when CO2 rises during an apneic episode. Animal research confirms that OX2R blockade reduces hypercapnic arousal responses, which directly worsens apnea severity in susceptible animals. The clinical implication: suvorexant should be used with particular caution in OSA patients perioperatively, and the hold recommendation is stronger for this subgroup.

Patients with OSA on suvorexant should bring their CPAP device to the hospital. CPAP use in the PACU is supported by ASA practice guidelines for OSA patients and partially compensates for suvorexant's residual suppression of arousal reflexes in the first 12 hours after the last dose.

Obesity and Extended Half-Life

Suvorexant is highly lipophilic (logP approximately 3.8). In obese patients, volume of distribution increases, which may extend the effective half-life beyond the label's stated 12-hour mean. A pharmacokinetic substudy showed that body weight was not a statistically significant covariate in the population PK model, but individual variability was wide. Anesthesiologists managing patients with BMI above 35 who took suvorexant within 12 hours of surgery should plan for potentially prolonged sedation during emergence.

Reversal: Is There an Antidote?

There is no approved pharmacological reversal agent for suvorexant. Flumazenil reverses benzodiazepines; naloxone reverses opioids. Neither reverses orexin receptor blockade. The only management for excessive suvorexant sedation is supportive care: airway protection, supplemental oxygen, stimulation to maintain respiratory drive, and time.

Suvorexant's protein binding is greater than 99%, making hemodialysis ineffective for accelerating clearance. Activated charcoal may reduce absorption if administered within one hour of an overdose, per standard toxicological principles published by Poison Control guidelines, but is not applicable in the surgical setting.

Orexin agonist compounds (e.g., TAK-994, an OX2R agonist in trials per ClinicalTrials.gov NCT04091438) are under investigation for narcolepsy and could theoretically reverse orexin antagonist effects, but none is approved or available for clinical reversal use as of early 2025.

Practical Monitoring in the PACU

The absence of a reversal agent reinforces why prevention (holding the drug preoperatively) is the primary strategy. When suvorexant was not held before surgery, the PACU team should:

1. Apply continuous pulse oximetry through the full recovery period
2. Use standardized sedation scoring (Ramsay or Richmond Agitation-Sedation Scale) every 15 minutes
3. Delay opioid dose escalation until the patient demonstrates spontaneous, sustained respiratory effort
4. Keep reversal agents (flumazenil, naloxone) at bedside to address any co-prescribed CNS depressants, even though neither reverses suvorexant directly

A Cochrane review of PACU respiratory events identified preoperative sedative use as a significant independent predictor of PACU oxygen desaturation below 90%. Suvorexant fits this risk profile.

Drug-Drug Interactions Beyond Anesthesia

Suvorexant's interaction profile extends beyond the OR. The following interactions are relevant to the broader perioperative medication reconciliation:

Opioid analgesics (continued postoperative use). Hydrocodone, oxycodone, and morphine all carry additive CNS-depression risk with suvorexant. The FDA opioid prescribing guidance explicitly warns that concurrent use of opioids with other CNS depressants requires dose reduction of one or both agents and enhanced monitoring.

Gabapentinoids. Pregabalin and gabapentin, increasingly used for perioperative pain management, are CNS depressants. A 2019 BMJ meta-analysis (N=8,975 patients across 281 trials) found gabapentinoids increased serious adverse events including sedation and respiratory depression when added to opioids. Adding suvorexant to this combination creates a three-way CNS-depressant stack.

Antiemetics. Promethazine and droperidol, used postoperatively for nausea, carry sedating properties. The FDA black-box warning for promethazine references respiratory depression risk; concurrent suvorexant use amplifies this concern.

Muscle relaxants. Non-depolarizing neuromuscular blockers (rocuronium, vecuronium) are reversed with sugammadex or neostigmine. Residual neuromuscular blockade combined with suvorexant-mediated reduced arousal increases the risk that a patient will not be able to protect their airway independently during PACU recovery.

Communicating Suvorexant Use to Your Care Team

Patients commonly do not report sleep aids on medication history forms. A survey published in the Journal of Clinical Anesthesia found that up to 38% of surgical patients omitted at least one prescription medication from their preoperative history, with sleep aids and psychiatric medications among the most frequently missed categories.

The HealthRX clinical recommendation: list suvorexant by both its brand name (Belsomra) and generic name (suvorexant) on every preoperative medication form. Include the dose and the time of the last tablet taken. If the preoperative nurse or surgeon's office does not ask about sleep medications specifically, raise it proactively at the pre-admission call.